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Osteoporosis has been named “the silent disease” because there are no symptoms until 
a fragility fracture occurs. With the rapid rise in the elderly population, the number of 
patients with osteoporosis and fragility fractures has increased in most developed coun-
tries. Fragility fractures increase societal burdens in terms of mortality and quality of 
life, as well as economic costs. Fragility fractures of the hip have the most impact on the 
ambulatory status of the elderly and its incidence is reported to be lower among Asians or 
Africans than Caucasians. Increases in the age-specific and gender-specific incidence of 
hip fracture with time have been reported in Asian countries, including Japan; however, 
studies in North America, Europe and Oceania have reported decreases in the incidence. 
A new fragility fracture increases fracture risk, resulting in possible recurrence or other 
new fractures. The most important strategy for preventing such fractures is a systematic 
approach to educating and following patients in the immediate postoperative period after 
the initial fragility fracture.
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Japan currently has the largest aged population, 
and it is expected to increase until 2050 while the 
total population decreases (Fig. 1). Even among the 
developing countries, graying of the population will 
become a serious concern in the future. With the 
rapid increase in the elderly population, the number 
of patients with osteoporosis and fragility fractures 
have increased in most developed countries. Fragil-
ity fractures increase societal burdens with respect 
to mortality, quality of life (QOL), and economic 
costs. The combined annual cost of all osteoporotic 
fractures has been estimated to be $20 billion in 
the Uninted States and €30 billion in the European 
Union (Cummings and Melton, 2002; Cooper et al., 
2011). Fractures account for about 1–2% of the total 
health care costs, of which inpatient care costs dom-
inate. Although fractures affect older people to a 
larger extent, indirect costs, such as the loss in pro-
ductivity due to sick leave, also play an important 
role that has been estimated at approximately 10% 
of the total costs (Zethraeus et al., 2007). In Japan, 
the annual cost for the treatment of hip fractures is 
estimated to be approximately ¥130 billion, exclud-
ing the cost of patient care after discharge (Com-
mittee for Osteoporosis Treatment of The Japanese 
Orthopaedic Association, 2004).  
 A new fragility fracture does not only reduce 
daily activity but can also increase fracture risk, 
resulting in possible recurrence or other new frac-
tures: “fracture begets fracture.” However, it is re-
ported that the vast majority of patients who experi-
ence a hip fracture do not receive anti-osteoporotic 
therapy after the fracture (Cadarette et al., 2008; 
Roerholt et al., 2009). In Japan, there is a paucity of 
data available on the proportion of patients with a 
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new fragility fracture who are started on an inter-
vention (Hagino et al., 2012). Novel strategies are 
required to disseminate and implement best prac-
tices at the point of care to reduce the risk of recur-
rent fractures. In this review, the current status of 
osteoporosis and fragility fractures and strategies to 
reduce their burden are discussed. 
 
What are osteoporosis and  
fragility fractures?
 
Osteoporosis
 
Osteoporosis has been named “the silent disease” 
since there are no symptoms until a fracture occurs 
after minimal trauma. Osteoporosis is a skeletal dis-
order characterized by compromised bone strength 
predisposing a person to an increased risk of frac-
ture. Bone strength primarily reflects a combination 
of bone density and bone quality (NIH Consensus 
Development Panel, 2001). A fragility fracture oc-
curs when a failure-inducing force such as trauma 
is applied to osteoporotic bone (NIH Consensus De-
velopment Panel, 2001). Bone density is expressed 
as grams of mineral per area or volume, which is 
measured by bone densitometry. Bone quality re-
fers to its architecture (macro and micro), turnover, 
damage accumulation (e.g., microfractures) and 
mineralization. Bone quality is thought to be the 
part of bone strength that is not explained by bone 
density, which is estimated to be 30% of total bone 
strength (NIH Consensus Development Panel, 2001). 
 In 2005, there were an estimated 13 million 
patients with osteoporosis in Japan. This number 
was calculated from the data on bone density in 
healthy Japanese subjects and the diagnostic criteria 
for primary osteoporosis.
 
Fragility fractures
 
Fragility fractures are thought to be osteoporosis-
related geriatric fractures, as opposed to traumatic 
fractures. However, there is no conclusive definition 
for fragility fracture. Based on the recent papers, 
fragility fractures are those due to mild injuries, 
such as a fall from standing height, and not occur-
ring as a result of significant trauma, such as a mo-
tor vehicle collision (ASBMR Task Force on Osteo-
porotic Fracture Secondary Prevention, in press).
 
Incidence of fragility fractures
 
Among the Japanese population, the age-specific 
and gender-specific incidence of hip fractures in-
creased exponentially after 70 years of age (Fig. 2) 
Fig. 1. Population projections for Japan. The total popula-
tion of Japan is projected to decrease until 2050 but a sub-
stantial increase in the proportion aged 85 years and over is 
expected. (Data source: National Institute of Population and 
Social Security Research; http://www.ipss.go.jp/syoushika/
tohkei/newest04/sh2401smm.html)
Fig. 2. Age-specific and gender-specific incidences of hip frac-
tures in Japan. The age-specific and gender-specific incidence 
of hip fractures increases exponentially with age after 70 years 
in both men and women. Adapted from: Hagino et al., 2009a; 
Orimo et al., 2009; Arakaki et al., 2011.
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(Hagino et al., 2009a; Orimo et al., 2009; Arakaki 
et al., 2011). Based on the incidence in Tottori Pre-
fecture, Japan, the annual number of patients with 
new hip fractures is estimated to be approximately 
190,000 in 2012 and 320,000 in 2040 (Fig. 3).
 There have been many epidemiological 
surveys of hip fractures worldwide. One of the 
conclusions derived from these studies is that the 
incidence of hip fractures is lower among Asian or 
African populations than Caucasian populations. 
Table 1 compares the incidence of hip fractures 
among different populations based on studies from 
Japan , China (Yan et al., 1999), Korea (Lim et 
al., 2008), Turkey (Tuzun et al., 2011), Argentina 
(Morosano et al., 2005), Finland (Lönnroos et al., 
2006) and Norway (Bjørgul and Reikerås, 2007). 
Incidences for both genders in Asian populations, 
including Japanese, are substantially lower than 
those in Caucasian populations living in Northern 
Europe or South America. Since Asians are known 
to have similar or lower bone mass than Caucasians, 
differences in bone mass do not explain the differ-
ences in the incidence of hip fractures. Elucidating 
the causes for ethnic differences in the incidence of 
hip fractures may suggest preventive measures that 
could protect against fragility fractures. Therefore, 
several approaches have been tried to explain why 
hip fracture incidence is lower in Asian populations. 
One hypothesis is the different risk of falls between 
Asians and Caucasians (Aoyagi et al., 1998), pre-
sumably based on differences in lifestyles. It was 
reported that aspects of the Japanese lifestyle, such 
as drinking Japanese tea and the use of a futon, 
are effective for preventing fractures (Suzuki et al., 
1997; Hagino et al., 2004). However, there have 
been no conclusive explanations for the differences 
observed.
 Recent data from Asia, including Japan, 
showed an increase in the age-specific and gender-
specific incidence of hip fractures over time (Hagino 
et al., 2009a; Arakaki et al., 2011; Xia et al., 2011). 
In Japan, a steady increase has been observed 
for 20 years in Tottori (Hagino et al., 2009a) and 
Okinawa (Arakaki et al., 2011) Prefectures (Fig. 4). 
In Beijing, China, the incidence of hip fractures 
rose very rapidly from 2002 to 2006, about 10% 
Table 1. Comparison of the incidence of hip fractures among dif-
ferent populations
 
 Geographic area Survey year Men Women
 
Japan Tottori Prefecture 2004–2006 94.9  326.6
Japan Okinawa Prefecture 2004 89.8  329.0
Japan Nationwide 2007 94.2  324.5
China  Shenyang 1994 72.2  65.2
Korea Nationwide 2001–2004 164.5  290.4
Turkey 12 regions 2009 89.8  432.3
Argentina Rosario 2001–2002 116.7  479.4
Finland  Central Finland 2002–2003 195.6  399.6
Norway  Southeastern Norway 1998–2003 264.4  615.5 
 
 Data are incidences (per 100,000 person-years) adjusted to the population 
structure for all of Japan in 2010 (≥ 35 years).
Fig. 3. Expected number of patients with hip fractures in 
Japan. Approximately 190,000 hip fractures are expected to 
occur in 2012, and the estimate increases up to more than 
300,000 for 2040 based on the incidence in Tottori Prefec-
ture, Japan. (Data source: National Institute of Population 
and Social Security Research; http://www.ipss.go.jp/syou-
shika/tohkei/newest04/sh2401smm.html)
per year (Xia et al., 2011). It is 
speculated that the increased risk 
of hip fracture is due to the changes 
in lifestyle with urbanization. On 
the other hand, studies in North 
America, Europe and Oceania have 
generally reported increases in hip 
fracture incidence through the sec-
ond half of the 20th century, but 
those continuing to follow trends 
over the last 2 decades have found 
that rates have stabilized with age-
adjusted decreases being observed 
in certain centers (Cooper et al., 
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2011). However, no conclusive cause has been 
elucidated for why the incidence in North 
America, Europe and Oceania are decreasing 
and why those in Asia are increasing.
 In contrast to the incidence of the limb 
fractures, epidemiological surveys found a 
higher incidence of incident vertebral fractures 
evaluated morphometrically among the Japa-
nese (Fujiwara et al., 2003) than in European 
counterparts (Van der Klift et al., 2002; Euro-
pean Prospective Osteoporosis Study Group, 
2002). The prevalence of vertebral fractures is 
also higher among the Japanese population than 
the Caucasian population in the United States 
(Ross et al., 1995). It is suspected that small 
bone size or lifestyle differences, including low 
calcium intake, are responsible for this differ-
ence; however, there are no studies to explain 
this difference.
ter the first hip fracture and then plateau (Yamanashi 
et al., 2005; Hagino et al., 2012).  A recent nation-
wide study in Denmark involving a large number of 
hip fracture patients demonstrated that the risk of a 
second hip fracture was 12-fold higher at 1 month 
and more than doubled at 1 year (Ryg et al., 2009). 
These findings indicate that the period immediately 
following the first fracture is a window of opportu-
nity for implementing a fracture prevention strategy. 
Burden of fragility fractures
 
Changes in ambulatory ability 
 
Hip fracture is the fragility facture with the high-
est impact on the ambulatory status of the elderly. 
A fixed-point observation project involving core 
orthopedic hospitals throughout Japan examined 
a larger number of variables including the 1-year 
prognosis (Sakamoto et al., 2006). In this study, 
a total of 10,992 hip fractures were enrolled from 
1999 to 2001 and a 24.1% decrease in the number 
of patients who were independently ambulatory was 
observed at 1 year after fracture. In a recent large 
prospective study, changes in ambulatory ability af-
ter hip fracture were evaluated (Fukui et al., 2012). 
Fig. 4. Recent changes in the incidence of hip fractures in Japan. 
The number of patients with hip fractures calculated from previ-
ous surveys from Tottori (Hagino et al., 2009a), Niigata (Morita 
et al., 2002) and Okinawa (Arakaki et al., 2011) Prefectures and 
throughout the country (Orimo et al., 2009) are shown. Data are 
adjusted to the population structure (2010 Japan).
Risk of a second fracture 
 
Investigators from Rochester, Minnesota described 
the epidemiology of hip fractures in their locality 
during the period between 1965 and 1974. They 
found that 68% of women and 59% of men had 
experienced at least 1 other fracture prior to break-
ing their hip (Gallagher et al., 1980), suggesting that 
almost one-half of today’s hip fracture patients have 
suffered prior fractures (ASBMR Task Force on Os-
teoporotic Fracture Secondary Prevention, in press). 
Very little data is available on the risk of sustaining a 
second hip fracture after an initial hip fracture in the 
Asian population, although there is a large difference 
in the incidence of fragility fractures between Asians 
and Caucasians. Recently we performed a registry-
based study consisting of 2,328 patients with first hip 
fracture treated in 25 hospitals in Japan (Prevention 
of Second Hip Fracture study; POSHIP) (Hagino et 
al., 2012). The 1-year incidence rate as determined in 
the POSHIP study was 3.40% and rate ratio of a sec-
ond hip fracture compared to the general population 
in Japan was as high as 4.0.
 The likelihood of sustaining a second hip frac-
ture tended to rise during the first 6 or 8 months af-
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In this cohort, patients who sustained hip fractures 
suffered obvious deterioration in ambulatory ability 
and the number of ambulatory subjects in the com-
munity setting was nearly halved 6 months after 
surgery, whereas that of patients who cannot walk 
unaided was almost doubled. In a retrospective 10-
year observational study, the proportion of patients 
who were able to walk outdoors alone, with or with-
out an assistive device, was 68% before a hip frac-
ture and 56% at 1 year afterwards, and remained 
stable for 10 years (Tsuboi et al., 2007).
 
Mortality
 
In a prospective study in Japan, the 1-year mortal-
ity rate for the entire hip fracture patient population 
was 10.1% (Sakamoto et al., 2006). In a retrospec-
tive study, the survival rate decreases rapidly for 2 
years after fracture before stabilizing (Tsuboi et al., 
2007).  However, the survival rate was still well be-
low that of the general population for up to 10 years 
and the increased mortality risk was approximately 
double that of the general population. 
 A comparative study of hip fractures with a 
median follow-up duration of 276 days after sur-
gery demonstrated that the survival rate was 89.5% 
in Japan and 77.2% in the United States (Kondo et 
al., 2010). Japanese patients had a significantly lon-
ger length of hospital stay after surgery but higher 
survival rates than American patients, and longer 
length of hospital stay after surgery was associated 
with a lower risk of mortality after discharge after 
adjusting for patient characteristics and country. 
 
Quality of life
 
In a prospective observational study, health-related 
QOL was evaluated by Euroqol (EQ5D) in elderly 
women following incident hip, vertebral and wrist 
fractures (Hagino et al., 2009b). The reduction in 
EQ5D values was greatest in the hip fracture group 
during the observational period. EQ5D values at 
6 months after fracture in the wrist fracture group 
showed recovery; however, at 6 months the hip and 
vertebral fracture groups had EQ5D scores that 
were significantly lower than pre-fracture scores. 
At 1 year after fracture, EQ5D values were not sig-
nificantly different from pre-fracture values for the 
vertebral and wrist fracture groups; however, they 
remained significantly lower for the hip fracture 
group. Another recent study demonstrated that men 
and women with hip and clinical vertebral fractures 
and women with rib fractures had adverse changes 
in their QOL but forearm and pelvic fractures did 
not appear to substantially influence QOL scores 
(Papaioannou et al., 2009).
 
Prevention of fragility fractures
 
Who are the targets? 
 
It is well established that a history of a prior frac-
ture at any site is an important risk factor for fu-
ture fractures (Klotzbuecher et al., 2000). Patients 
with a history of a prior fracture, therefore, should 
receive further evaluation and treatment for osteo-
porosis to prevent subsequent fractures. However, 
it is reported that the vast majority of patients who 
experience a hip fracture as well as other fragility 
fractures do not receive anti-osteoporotic therapy 
after fracture (Cadarette et al., 2008; Roerholt et al., 
2009). Among patients who begin anti-resorptive 
osteoporosis treatment after fracture, adherence to 
treatment decreases over time and remains subopti-
mal (Roerholt et al., 2009; Rabenda et al., 2008).  It 
was recently reported that the situation has not im-
proved; in 2007 to 2008, fewer than 20% of untreat-
ed individuals with a low-trauma fracture received 
intervention despite increased attention to gaps in 
post-fracture osteoporosis management in the last 
10 years (Leslie et al., 2012).  The POSHIP study 
found a high risk of a second hip fracture during the 
1-year period after the initial fracture; however, an-
ti-osteoporosis pharmacotherapy was given in only 
18.7% and 53.3% received no treatment (Hagino et 
al., 2012). Thus, inadequate treatment after the first 
hip fracture is now evident as well as other fragility 
fractures. 
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Fracture liaison service
 
A systematic approach is important for educating 
and following patients in the immediate postopera-
tive period after a hip fracture as well as for other 
fragility fractures in order to provide adequate inter-
vention for patients at high risk for subsequent frac-
ture (Gardner et al., 2005; Rozental et al., 2008).  In 
the United Kingdom, Canada and the United States, 
a consensus on systematic and multidisciplinary ap-
proaches to secondary fragility fracture prevention, 
called the Fracture Liaison Service (FLS), has been 
developed over the last decade (Mitchell, 2011). 
The FLS is operated by mainly nurse specialists 
supported by a lead clinician in osteoporosis. They 
identify patients with new fragility fractures who 
are either admitted to the orthopedic inpatient ward 
or managed as outpatients through the fracture clin-
ic and then arrange for appropriate patients to attend 
the FLS clinic where bone density is measured. 
After bone mass measurement, the nurse specialist 
assesses future fracture risk by taking the patient’s 
history. If necessary, the nurse informs the patient 
of the risk for osteoporosis, and then provides a let-
ter to give to the primary physician. Such systematic 
approaches have been started globally in campaigns 
such as “Capture the Fracture” (International Os-
teoporosis Foundation).
 
Anti-osteoporosis drugs 
 
The recent development of anti-osteoporosis drugs, 
especially anti-resorptive agents, has revolutionized 
the field of fracture prevention. It is now known that 
oral bisphosphonate treatment for 3 years (Osaki et 
al., 2012) or an annual infusion of zoledronic acid 
for 1.9 years (Black et al., 2007) after a hip fracture 
is associated with a reduction in the rate of new 
clinical fractures including hip fracture, as well as 
an improvement in survival (Lyles et al., 2007). 
Since bisphosphonates can reduce the incidence 
of fragility fractures, including hip fractures, in 
patients with osteoporosis, they have become first-
line drugs for the treatment of osteoporosis. Though 
bisphosphonates have a relatively good safety re-
cord and are well tolerated by most patients, serious 
adverse events have been associated with their use. 
Over the past few years, there has been growing 
concern about the potential relationship between 
long-term use of bisphosphonates and osteonecro-
sis of the jaw (ONJ) and atypical femoral fractures 
(AFF) (Fig. 5).  Regarding AFF, recent nationwide 
population-based analyses were reassuring for pa-
tients receiving bisphosphonates (Schilcher et al., 
2011). Recently, a survey of AFF was conducted in 
Japan (Hagino, 2011).  The 3,116 hospitals surveyed 
reported 398 cases of AFF, of which 29.9% were 
associated with previous bisphosphonate therapy. 
Although there seems to be a higher prevalence of 
current bisphosphonate use among patients with 
AFF or ONJ, the absolute risk of these complica-
tions is very small and the beneficial effects of 
bisphosphonates far outweigh these risks.
 In addition to anti-resorptive agents, an ana-
bolic agent, teriparatide, is available and widely 
used globally. Many clinical trials have found that 
teriparatide can reduce the incidence of new frac-
tures (Neer et al., 2001). Recently, weekly teripa-
Fig. 5.  Case of an atypical femoral fracture. An 81-year-old 
women suffered a right femoral shaft fracture upon falling 
on the road. She has been on alendronate for 6 years. Com-
plete fractures extend through both cortices and a medial 
spike of the right femur was observed on a radiograph (left 
panel). An increase in the cortical thickness of the diaphysis 
of the lateral cortex of the left femur is noted (right panel; 
arrow).
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ratide became available in Japan for the treatment 
of osteoporosis.  Teriparatide has a potential for 
desired effects in secondary fracture prevention 
(Nakamura et al., 2012).
 
Conclusion:  A rapid increase in the number of 
patients with fragility fractures is projected in many 
Asian counties, including Japan. The most impor-
tant strategy for preventing such fractures is a mul-
tidisciplinary approach for educating and following 
patients in the immediate postoperative period after 
the initial fragility fracture.
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